

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

InVivoPlus anti-mouse PD-1 (CD279)

RRID:AB_1107747

Type: Antibody

Proper Citation

Bio X Cell Cat# BE0033-2, RRID:AB_1107747

Antibody Information

URL: http://antibodyregistry.org/AB_1107747

Proper Citation: Bio X Cell Cat# BE0033-2, RRID:AB_1107747

Target Antigen: PD-1 (CD279)

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization

Consolidation on 12/2021: AB_1107747, AB_2894791.

Antibody Name: InVivoPlus anti-mouse PD-1 (CD279)

Description: This monoclonal targets PD-1 (CD279)

Target Organism: mouse

Clone ID: clone J43

Antibody ID: AB_1107747

Vendor: Bio X Cell

Catalog Number: BE0033-2

Alternative Catalog Numbers: BE0033-2-1MG, BP0033-2-100MG, BP0033-2-50MG, BE0033-2-25MG, BP0033-2-5MG, BE0033-2-5MG, BE0033-2-50MG, BE0033-2-100MG, BP0033-2-25MG

Record Creation Time: 20250820T065136+0000

Record Last Update: 20250821T010503+0000

Ratings and Alerts

No rating or validation information has been found for InVivoPlus anti-mouse PD-1 (CD279).

No alerts have been found for InVivoPlus anti-mouse PD-1 (CD279).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Jiang Y, et al. (2025) Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs. *Cell*, 188(9), 2354.

Oswald BM, et al. (2025) Dietary restriction reprograms CD8+ T cell fate to enhance anti-tumour immunity and immunotherapy responses. *Nature metabolism*, 7(12), 2489.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. *Cancer cell*, 43(3), 428.

Wu S, et al. (2023) Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment. *Cancer research communications*, 3(8), 1460.

Rossignol J, et al. (2022) Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1. *iScience*, 25(6), 104353.

Brinch SA, et al. (2022) The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models. *Cancer research communications*, 2(4), 233.

Meng J, et al. (2022) Tumor-derived Jagged1 promotes cancer progression through immune evasion. *Cell reports*, 38(10), 110492.

Teijeira A, et al. (2022) Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy. *Cancer research*, 82(23), 4373.

Sharma MD, et al. (2021) Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. *Immunity*, 54(10), 2354.

Kato D, et al. (2020) GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. *eLife*, 9.

Rudd CE, et al. (2020) Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity. *Cell reports*, 30(7), 2075.

Hu Z, et al. (2019) Acylglycerol Kinase Maintains Metabolic State and Immune Responses of CD8⁺ T Cells. *Cell metabolism*, 30(2), 290.

Li J, et al. (2018) Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8⁺ T Cells. *Immunity*, 48(4), 773.

Xia Y, et al. (2018) The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. *Cell*, 175(4), 1059.

Sharma MD, et al. (2018) Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c⁺CD103⁺ Monocytic Antigen-Presenting Cells in Tumors. *Immunity*, 48(1), 91.